This company has been marked as potentially delisted and may not be actively trading.

AV Homes (AVHI) Competitors

AVHI vs. FOR, BTTX, UPHL, HYPR, and IMUX

Should you be buying AV Homes stock or one of its competitors? The main competitors of AV Homes include Forestar Group (FOR), Better Therapeutics (BTTX), UpHealth (UPHL), Hyperfine (HYPR), and Immunic (IMUX).

How does AV Homes compare to Forestar Group?

Forestar Group (NYSE:FOR) and AV Homes (NASDAQ:AVHI) are both small-cap real estate development companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

: Forestar Group has higher revenue and earnings than AV Homes. AV Homes is trading at a lower price-to-earnings ratio than Forestar Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Forestar Group $1.66B 0.82 $167.90M $3.28 8.14
AV Homes N/A N/A -$2.58M -$1.23 N/A
: 35.5% of Forestar Group shares are held by institutional investors. Comparatively, 16.3% of AV Homes shares are held by institutional investors. 0.5% of Forestar Group shares are held by company insiders. Comparatively, 51.5% of AV Homes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Forestar Group has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, AV Homes has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.
: In the previous week, Forestar Group had 3 more articles in the media than AV Homes. MarketBeat recorded 3 mentions for Forestar Group and 0 mentions for AV Homes. Forestar Group's average media sentiment score of 0.38 beat AV Homes' score of 0.00 indicating that Forestar Group is being referred to more favorably in the media.
Company Overall Sentiment
Forestar Group Neutral
AV Homes Neutral
: Forestar Group has a net margin of 9.80% compared to AV Homes' net margin of 0.00%. Forestar Group's return on equity of 9.49% beat AV Homes' return on equity.
Company Net Margins Return on Equity Return on Assets
Forestar Group 9.80% 9.49% 5.31%
AV Homes N/A N/A -38.71%
: Forestar Group presently has a consensus price target of $32.67, suggesting a potential upside of 22.29%. Given Forestar Group's stronger consensus rating and higher probable upside, research analysts plainly believe Forestar Group is more favorable than AV Homes.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forestar Group
0 Sell rating(s)
4 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
AV Homes
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forestar Group	$1.66B	0.82	$167.90M	$3.28	8.14
AV Homes	N/A	N/A	-$2.58M	-$1.23	N/A

Company	Overall Sentiment
Forestar Group	Neutral
AV Homes	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Forestar Group	9.80%	9.49%	5.31%
AV Homes	N/A	N/A	-38.71%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forestar Group	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
AV Homes	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Forestar Group beats AV Homes on 14 of the 15 factors compared between the two stocks.

How does AV Homes compare to Better Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and AV Homes (NASDAQ:AVHI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

: AV Homes is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Better Therapeutics N/A N/A -$39.76M -$0.78 N/A
AV Homes N/A N/A -$2.58M -$1.23 N/A
: Better Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, AV Homes has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
: 34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of AV Homes shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 51.5% of AV Homes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled AV Homes'average media sentiment score.
Company Overall Sentiment
Better Therapeutics Neutral
AV Homes Neutral
: Company Net Margins Return on Equity Return on Assets
Better Therapeutics N/A N/A N/A
AV Homes N/A N/A -38.71%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Better Therapeutics	N/A	N/A	-$39.76M	-$0.78	N/A
AV Homes	N/A	N/A	-$2.58M	-$1.23	N/A

Company	Overall Sentiment
Better Therapeutics	Neutral
AV Homes	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Better Therapeutics	N/A	N/A	N/A
AV Homes	N/A	N/A	-38.71%

Summary

Better Therapeutics beats AV Homes on 5 of the 7 factors compared between the two stocks.

How does AV Homes compare to UpHealth?

AV Homes (NASDAQ:AVHI) and UpHealth (NYSE:UPHL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

: In the previous week, AV Homes' average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.
Company Overall Sentiment
AV Homes Neutral
UpHealth Neutral
: AV Homes has higher earnings, but lower revenue than UpHealth. AV Homes is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AV Homes N/A N/A -$2.58M -$1.23 N/A
UpHealth $130M 0.00 -$56.42M $1.47 N/A
: Company Net Margins Return on Equity Return on Assets
AV Homes N/A N/A -38.71%
UpHealth N/A N/A N/A
: AV Homes has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Comparatively, UpHealth has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
: 16.3% of AV Homes shares are owned by institutional investors. Comparatively, 56.1% of UpHealth shares are owned by institutional investors. 51.5% of AV Homes shares are owned by company insiders. Comparatively, 34.2% of UpHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Overall Sentiment
AV Homes	Neutral
UpHealth	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AV Homes	N/A	N/A	-$2.58M	-$1.23	N/A
UpHealth	$130M	0.00	-$56.42M	$1.47	N/A

Company	Net Margins	Return on Equity	Return on Assets
AV Homes	N/A	N/A	-38.71%
UpHealth	N/A	N/A	N/A

Summary

UpHealth beats AV Homes on 6 of the 8 factors compared between the two stocks.

How does AV Homes compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and AV Homes (NASDAQ:AVHI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

: Hyperfine currently has a consensus target price of $1.59, indicating a potential downside of 7.16%. Given Hyperfine's stronger consensus rating and higher probable upside, analysts clearly believe Hyperfine is more favorable than AV Homes.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperfine
1 Sell rating(s)
2 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.33
AV Homes
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Hyperfine had 8 more articles in the media than AV Homes. MarketBeat recorded 8 mentions for Hyperfine and 0 mentions for AV Homes. Hyperfine's average media sentiment score of 0.36 beat AV Homes' score of 0.00 indicating that Hyperfine is being referred to more favorably in the media.
Company Overall Sentiment
Hyperfine Neutral
AV Homes Neutral
: AV Homes has lower revenue, but higher earnings than Hyperfine. AV Homes is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hyperfine $11.40M 14.69 -$35.57M -$0.44 N/A
AV Homes N/A N/A -$2.58M -$1.23 N/A
: AV Homes has a net margin of 0.00% compared to Hyperfine's net margin of -262.29%. AV Homes' return on equity of 0.00% beat Hyperfine's return on equity.
Company Net Margins Return on Equity Return on Assets
Hyperfine -262.29% -95.09% -71.11%
AV Homes N/A N/A -38.71%
: Hyperfine has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, AV Homes has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.
: 15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 16.3% of AV Homes shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by insiders. Comparatively, 51.5% of AV Homes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
AV Homes	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Hyperfine	Neutral
AV Homes	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	14.69	-$35.57M	-$0.44	N/A
AV Homes	N/A	N/A	-$2.58M	-$1.23	N/A

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-262.29%	-95.09%	-71.11%
AV Homes	N/A	N/A	-38.71%

Summary

Hyperfine beats AV Homes on 9 of the 15 factors compared between the two stocks.

How does AV Homes compare to Immunic?

Immunic (NASDAQ:IMUX) and AV Homes (NASDAQ:AVHI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

: 51.8% of Immunic shares are owned by institutional investors. Comparatively, 16.3% of AV Homes shares are owned by institutional investors. 14.0% of Immunic shares are owned by insiders. Comparatively, 51.5% of AV Homes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Immunic currently has a consensus target price of $52.43, indicating a potential upside of 364.79%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than AV Homes.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunic
1 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

3 Strong Buy rating(s)
3.00
AV Homes
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Immunic has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, AV Homes has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.
: In the previous week, Immunic had 15 more articles in the media than AV Homes. MarketBeat recorded 15 mentions for Immunic and 0 mentions for AV Homes. AV Homes' average media sentiment score of 0.00 beat Immunic's score of -0.11 indicating that AV Homes is being referred to more favorably in the news media.
Company Overall Sentiment
Immunic Neutral
AV Homes Neutral
: AV Homes is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immunic N/A N/A -$97.17M -$7.00 N/A
AV Homes N/A N/A -$2.58M -$1.23 N/A
: AV Homes' return on equity of 0.00% beat Immunic's return on equity.
Company Net Margins Return on Equity Return on Assets
Immunic N/A -1,197.81% -264.95%
AV Homes N/A N/A -38.71%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
AV Homes	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Immunic	Neutral
AV Homes	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$7.00	N/A
AV Homes	N/A	N/A	-$2.58M	-$1.23	N/A

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-1,197.81%	-264.95%
AV Homes	N/A	N/A	-38.71%

Summary

Immunic beats AV Homes on 8 of the 14 factors compared between the two stocks.

Get AV Homes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVHI vs. The Competition

Export

Metric	AV Homes	Health services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$31.47M	$2.52M	$6.25B	$11.77B
Dividend Yield	N/A	N/A	2.74%	5.26%
P/E Ratio	-9.11	N/A	29.25	27.07
Price / Sales	N/A	N/A	504.68	73.47
Price / Cash	N/A	N/A	43.30	53.90
Price / Book	-4.55	N/A	9.67	6.69
Net Income	-$2.58M	-$39.76M	$3.55B	$332.64M

AV Homes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVHI AV Homes	N/A	$11.20 flat	N/A	N/A	$31.47M	N/A	N/A	N/A
FOR Forestar Group	4.1127 of 5 stars	$28.12 +0.6%	$32.67 +16.2%	N/A	$1.42B	$1.71B	8.57	290
BTTX Better Therapeutics	N/A	$0.00 flat	N/A	N/A	$4K	N/A	N/A	40
UPHL UpHealth	N/A	$0.00 flat	N/A	N/A	$2K	$130M	N/A	1,750
HYPR Hyperfine	1.8458 of 5 stars	$1.29 +0.8%	$1.45 +12.4%	N/A	$125.39M	$13.56M	N/A	190	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVHI) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AV Homes (AVHI) Competitors

AVHI vs. FOR, BTTX, UPHL, HYPR, and IMUX

How does AV Homes compare to Forestar Group?

Summary

How does AV Homes compare to Better Therapeutics?

Summary

How does AV Homes compare to UpHealth?

Summary

How does AV Homes compare to Hyperfine?

Summary

How does AV Homes compare to Immunic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVHI vs. The Competition

AV Homes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AV Homes (AVHI) Competitors

AVHI vs. FOR, BTTX, UPHL, HYPR, and IMUX

How does AV Homes compare to Forestar Group?

Summary

How does AV Homes compare to Better Therapeutics?

Summary

How does AV Homes compare to UpHealth?

Summary

How does AV Homes compare to Hyperfine?

Summary

How does AV Homes compare to Immunic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVHI vs. The Competition

AV Homes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools